SCHEMBL2987871

SCHEMBL2987871

CC(C)(C)OC(=O)Cc1ccc(Oc2ccc(C(=O)NCCc3ccc(Cl)cc3)cc2)c(CN)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 4/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
PPARG P37231 2/20 0.52
PPARD Q03181 2/20 0.52
ALDH1A1 P00352 1/20 0.52
FABP2 P12104 1/20 0.52
GAA P10253 2/20 0.49
MCHR1 Q99705 1/20 0.49
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
MAPT P10636 1/20 0.45
CYP2C19 P33261 1/20 0.45
GFER P55789 1/20 0.45
HTT P42858 1/20 0.45
PTGDR2 Q9Y5Y4 7/20 0.44
KMT2A Q03164 1/20 0.42
MAPK14 Q16539 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2989932 0.92 NPC1 (0.53) PPARASMN1; SMN2PPARGPPARDALDH1A1
SCHEMBL2986505 0.90 HTT (0.58) PPARASMN1; SMN2PPARGPPARDALDH1A1
SCHEMBL4078169 0.87 MCHR1 (0.55) PPARASMN1; SMN2PPARGPPARDALDH1A1
SCHEMBL5126360 0.87 PPARA (0.49) PPARASMN1; SMN2PPARGPPARDALDH1A1
SCHEMBL5126359 0.87 PPARA (0.47) PPARASMN1; SMN2PPARGPPARDALDH1A1
SCHEMBL2982220 0.86 PPARA (0.62) PPARASMN1; SMN2PPARGPPARDALDH1A1
SCHEMBL2986695 0.85 PTGDR2 (0.54) PPARASMN1; SMN2PPARGPPARDALDH1A1
SCHEMBL2983975 0.84 MAPT (0.55) PPARASMN1; SMN2PPARGPPARDALDH1A1
SCHEMBL2985684 0.81 GAA (0.53) PPARASMN1; SMN2PPARGPPARDALDH1A1
SCHEMBL2979962 0.81 LOXL2 (0.46) SMN1; SMN2ALDH1A1NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492437-B2 4-substituted phenoxyphenylacetic acid derivatives ARRAY BIOPHARMA INC. (US) 2013-07-23 US disclosed
EP-2057115-B9 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES ARRAY BIOPHARMA INC (US) 2012-12-26 EP disclosed
EP-2057115-B1 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES ARRAY BIOPHARMA INC (US) 2012-10-03 EP disclosed
US-20120202854-A1 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES ARRAY BIOPHARMA INC. (US) 2012-08-09 US disclosed
US-8183289-B2 4-substituted phenoxyphenylacetic acid derivatives ARRAY BIOPHARMA INC. (US) 2012-05-22 US disclosed
US-20100173955-A1 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES ARRAY BIOPHARMA INC. (US) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173955-A1 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES CD22, HRH2, CD74 PPARA 874/4885SMN1; SMN2 3361/4885PPARG 729/4885
US-20120202854-A1 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES CD22, HRH2, CD74 PPARA 874/4885SMN1; SMN2 3361/4885PPARG 729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.